Democrats Score Surprise Texas State Senate Win, Fueling Momentum Ahead of 2026 Midterms 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Trump Says Fed Pick Kevin Warsh Could Win Democratic Support in Senate Confirmation 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Christian Menefee Wins Texas Special Election, Narrowing GOP House Majority 
Peter Mandelson Resigns from Labour Party Amid Renewed Jeffrey Epstein Links 
U.S. Approves Over $6.5 Billion in Military Sales to Israel Across Three Defense Contracts 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
U.S. Government Faces Brief Shutdown as Congress Delays Funding Deal 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new Global Head of Corporate Affairs, a strategic move as the Danish drugmaker faces heightened scrutiny from U.S. President Donald Trump over drug pricing. Miley, formerly Senior Vice President of Government Affairs at AbbVie, announced his appointment on LinkedIn, with Novo Nordisk confirming the news to Reuters.
The company stated that Miley will officially join in early November, overseeing global communications and public affairs. His extensive experience in the U.S. pharmaceutical sector is expected to help Novo strengthen its political and regulatory strategies in its largest market—the United States. A company source noted that Miley’s top priority will be managing relations with the Trump administration, which has recently intensified pressure on pharmaceutical firms to reduce prices.
Miley’s appointment aligns with new CEO Mike Doustdar’s efforts to regain investor confidence through a broad restructuring initiative aimed at improving competitiveness in the growing obesity drug market, particularly against Eli Lilly. The overhaul involves cutting about 9,000 jobs worldwide, including 5,000 in Denmark and several in the U.S.
In his LinkedIn post, Miley expressed optimism about enhancing Novo’s global communication and public affairs, noting his upcoming relocation to Denmark. Industry insiders say other major pharma companies have also been recruiting public affairs experts with strong Republican ties to navigate Washington’s policy landscape.
Shares of Novo Nordisk and Eli Lilly dropped on Friday following Trump’s statement that the price of Ozempic—Novo’s diabetes drug containing the same ingredient as its popular weight-loss drug Wegovy—would be lowered.
Miley brings nearly two decades of experience in pharmaceutical government relations, with past roles at Abbott and Pfizer, making him a pivotal figure in Novo’s next phase of global engagement.
